Journal article

Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension


Authors listSommer, N.; Droege, F.; Gamen, K. E.; Geisthoff, U.; Gall, H.; Tello, K.; Richter, M. J.; Deubner, L. M.; Schmiedel, R.; Hecker, M.; Spiekerkoetter, E.; Wirsching, K.; Seeger, W.; Ghofrani, H. A.; Pullamsetti, S.

Publication year2018

JournalPulmonary Circulation

Volume number9

Issue number2

ISSN2045-8932

eISSN2045-8940

Open access statusGold

DOI Linkhttps://doi.org/10.1177/2045894018805406

PublisherWiley


Abstract
Pulmonary arterial hypertension (PAH) can be found in patients suffering from a loss-of-function mutation of the gene encoding for the activin receptor-like kinase 1 (ALK-1), a bone morphogenetic protein (BMP) type 1 receptor. Interestingly, ALK-1 mutations also lead to hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant disease characterized by arteriovenous malformations (AVMs) leading to potentially life-threatening bleeding complications such as epistaxis. Current therapeutic options for both diseases are limited and often only temporary or accompanied by severe side effects. Here, we report of a patient with a mutation of the ALK-1 gene suffering from both HHT and PAH. Recently, it was shown that tacrolimus increased ALK-1 signaling and had beneficial effects in selected end-stage PAH patients. We thus hypothesized that treatment with tacrolimus may prevent disease progression in this patient. Surprisingly, treatment with low-dose tacrolimus dramatically improved his HHT-associated epistaxis but did not attenuate progression of PAH.



Citation Styles

Harvard Citation styleSommer, N., Droege, F., Gamen, K., Geisthoff, U., Gall, H., Tello, K., et al. (2018) Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, Pulmonary Circulation, 9(2), Article 2045894018805406. https://doi.org/10.1177/2045894018805406

APA Citation styleSommer, N., Droege, F., Gamen, K., Geisthoff, U., Gall, H., Tello, K., Richter, M., Deubner, L., Schmiedel, R., Hecker, M., Spiekerkoetter, E., Wirsching, K., Seeger, W., Ghofrani, H., & Pullamsetti, S. (2018). Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Pulmonary Circulation. 9(2), Article 2045894018805406. https://doi.org/10.1177/2045894018805406



Keywords


ALK-1 mutationFK506Morbus OslerRESCUEStacrolimusVEGF

Last updated on 2025-10-06 at 10:56